RXRX RECURSION PHARMACEUTICALS INC

Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program

Altitude Lab Secures Small Business Administration Growth Fund Accelerator Grant to Launch Horizon, a Commercialization Partnering Program

The grant designates Altitude Lab as a top acceleration program for biotechnology startups

SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- Altitude Lab and the Small Business Administration (SBA) are pleased to announce Horizon, a commercialization program to connect startups to distributors, biopharma partners, and strategic investors in major biotech hubs nationwide, providing education on deal structures while driving awareness of Altitude Lab's resident startups. The program is funded by a , which Altitude Lab secured last week alongside 60 other top incubator and accelerator programs across the country.

"Most biotech startups require commercial partnerships to bring their therapies and innovations to patients and customers. While life science is the fastest-growing sector in Utah, connecting to biopharma and global distributors remains a major hurdle. Horizon aims to close this gap by bringing our entrepreneurs to established biotech hubs and developing lasting relationships with national strategic partners," said Chandana Haque, Executive Director at Altitude Lab.

To help connect and drive Horizon forward, Altitude has formed initial partnerships with industry leaders, including and , to support its launch this fall. 

"Altitude Lab's receipt of the Small Business Administration Growth Fund Accelerator Grant underscores their dedication to advancing innovation in Utah's biotech sector. It’s truly exciting to see this award go to Altitude Lab and we eagerly anticipate the positive impact the Horizon program will have on fostering vital partnerships and driving progress. Congratulations to Altitude Lab on this well-deserved achievement!" said Marla Trollan, Utah Director of the U.S. Small Business Administration. 

"The Utah Innovation Fund is unique in that it is a state-sponsored venture fund designed to help our deep tech entrepreneurs bridge the gap between technology feasibility and commercial success. Horizon is a program that naturally fits our mission, and we are thrilled to help Altitude connect Utah's leading startups to critical partners," said Gabi Tellez, Managing Director of the Utah Innovation Fund. 

"Wilson Sonsini launched our Salt Lake City practice because we've noted the state's huge strides in economic activity. We've been working with Altitude to help their startups navigate partnership agreements and IP strategy for three years. Supporting Horizon by helping Altitude and its startup connect with our national network is a continuation of the investment we are making in the region," said Matt Bresnahan, Partner at Wilson Sonsini Goodrich & Rosati.

The Horizon Program offers numerous benefits for founders, including:

  • Roadshow tours in San Francisco, Southern California, Boston, and other leading biotech geographies offer unique opportunities to connect innovators with commercial partners
  • Reverse pitches from biopharma and distributors to explore partnership opportunities
  • Increased deal exposure, opportunities, and access to new executive networks for mentoring
  • Facilitated meetings and networking opportunities with partners

Altitude is preparing for its first roadshows this fall and is seeking commercial partners and entrepreneurial organizations to host regional dinners and participate as mentors. Take the first step towards transformative innovation in health care by joining us on this exciting journey. Email with your interest in Horizon as the subject line to be included in the initial tours.

About Altitude Lab

is building a new, diverse generation of founders to seed the next cycle of health care innovation in Utah's BioHive. Currently located in Gateway's BioHive Hub in Salt Lake City, Altitude Lab is an incubator focused on early-stage life science and health care companies. The initiative is part of a larger city plan and collaborative vision from to foster socially responsible entrepreneurship, job creation, and economic productivity. The Recursion Foundation, under which Altitude Lab operates, is a 501(c)(3) nonprofit organization.

Learn more at or connect on .

About the U.S. Small Business Administration

The U.S. Small Business Administration helps power the American dream of business ownership. As the only go-to resource and voice for small businesses backed by the strength of the federal government, the SBA empowers entrepreneurs and small business owners with the resources and support they need to start, grow, expand their businesses, or recover from a declared disaster. It delivers services through an extensive network of SBA field offices and partnerships with public and private organizations. To learn more, visit . 

About Recursion

is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological, chemical and patient-centric datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology, chemistry and patient-centric data to advance the future of medicine. 

Recursion is headquartered in Salt Lake City, where it is a founding member of , the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal and the San Francisco Bay Area. Learn more at , or connect on (formerly Twitter) and .



Media Contact
 

Investor Contact
 
EN
30/04/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on RECURSION PHARMACEUTICALS INC

 PRESS RELEASE

Recursion Reports Grant of Inducement Awards as Permitted by the Nasda...

Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 820,431 shares of its class A common stock in the aggregate to 17 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award w...

 PRESS RELEASE

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference

Recursion to Present at 44th Annual J.P. Morgan Healthcare Conference Salt Lake City, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13, 10:30am PT at the upcoming 44th Annual J.P. Morgan Healthcare Conference in San Francisco. Management will also participate in the following upcoming investor conference: 28th Annual Needham Growth Conference - Friday, January 16, 2026 Webcasts may be found in th...

 PRESS RELEASE

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonst...

Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks off therapy (week 25 of the study), 82% of evaluable patients (9 of 11) maintained a durable reduction in total polyp burden, with a 53% median reduction observed from baselineNatural history analysis showed that 87% of unt...

 PRESS RELEASE

Recursion Announces Webinar For Upcoming Clinical Data Readout on the ...

Recursion Announces Webinar For Upcoming Clinical Data Readout on the TUPELO Phase 1b/2 Trial of REC-4881 in Familial Adenomatous Polyposis on December 8, 2025 Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a new clinical readout from the ongoing TUPELO Phase 1b/2 trial of REC-4881 in FAP at an upcoming company webinar. The webinar will be held on December 8, 2025 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT, and will be streamed live on Recurs...

 PRESS RELEASE

Recursion Reports Third Quarter 2025 Financial Results and Provides Bu...

Recursion Reports Third Quarter 2025 Financial Results and Provides Business Update Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map designed to accelerate treatments for a wide range of neurological diseasesWith this achievement, Recursion will have reached over $500 million in milestone and upfront payments across all its partnerships and collaborationsApproximately $785 million of cash and cash equivalents (unaudited) as of October 9, 2025- runway through the end of 2027, without additional financing...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch